Q1 2025 Earnings Forecast for Bristol-Myers Squibb Issued By Zacks Research (NYSE:BMY)

Bristol-Myers Squibb (NYSE:BMY) – Research analysts at Zacks Research lifted their Q1 2025 earnings per share estimates for Bristol-Myers Squibb in a report released on Wednesday, June 26th. Zacks Research analyst E. Bagri now expects that the biopharmaceutical company will post earnings of $1.80 per share for the quarter, up from their previous forecast of $1.79. The consensus estimate for Bristol-Myers Squibb’s current full-year earnings is $0.58 per share. Zacks Research also issued estimates for Bristol-Myers Squibb’s FY2025 earnings at $6.99 EPS.

A number of other analysts have also recently weighed in on the stock. Societe Generale cut shares of Bristol-Myers Squibb from a “buy” rating to a “hold” rating in a research note on Monday, March 11th. Barclays lowered their price objective on Bristol-Myers Squibb from $51.00 to $43.00 and set an “equal weight” rating on the stock in a research note on Friday, April 26th. William Blair restated a “market perform” rating on shares of Bristol-Myers Squibb in a research report on Monday, April 1st. StockNews.com cut Bristol-Myers Squibb from a “strong-buy” rating to a “buy” rating in a research report on Thursday. Finally, BMO Capital Markets cut their price objective on Bristol-Myers Squibb from $55.00 to $48.00 and set a “market perform” rating for the company in a report on Friday, April 26th. One analyst has rated the stock with a sell rating, fifteen have given a hold rating and four have issued a buy rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Hold” and a consensus price target of $60.00.

Bristol-Myers Squibb Trading Up 0.0 %

Shares of Bristol-Myers Squibb stock opened at $41.53 on Friday. The company’s fifty day moving average price is $42.97 and its two-hundred day moving average price is $48.16. The firm has a market capitalization of $84.19 billion, a PE ratio of -13.40, a price-to-earnings-growth ratio of 14.54 and a beta of 0.43. Bristol-Myers Squibb has a 52-week low of $39.63 and a 52-week high of $65.38. The company has a debt-to-equity ratio of 2.99, a current ratio of 1.11 and a quick ratio of 0.99.

Bristol-Myers Squibb (NYSE:BMY) last released its quarterly earnings data on Thursday, April 25th. The biopharmaceutical company reported ($4.40) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($4.53) by $0.13. The business had revenue of $11.87 billion for the quarter, compared to analysts’ expectations of $11.45 billion. Bristol-Myers Squibb had a positive return on equity of 8.83% and a negative net margin of 13.50%. Bristol-Myers Squibb’s quarterly revenue was up 4.7% on a year-over-year basis. During the same period in the previous year, the business posted $2.05 earnings per share.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the stock. McClarren Financial Advisors Inc. boosted its holdings in Bristol-Myers Squibb by 532.7% during the fourth quarter. McClarren Financial Advisors Inc. now owns 1,879 shares of the biopharmaceutical company’s stock worth $96,000 after buying an additional 1,582 shares during the last quarter. Institute for Wealth Management LLC. grew its holdings in Bristol-Myers Squibb by 1.0% during the fourth quarter. Institute for Wealth Management LLC. now owns 30,056 shares of the biopharmaceutical company’s stock valued at $1,542,000 after purchasing an additional 296 shares during the period. Great Diamond Partners LLC raised its holdings in Bristol-Myers Squibb by 9.2% in the fourth quarter. Great Diamond Partners LLC now owns 4,372 shares of the biopharmaceutical company’s stock worth $224,000 after purchasing an additional 367 shares during the period. Global Assets Advisory LLC bought a new position in shares of Bristol-Myers Squibb during the first quarter worth $5,161,000. Finally, Principal Securities Inc. acquired a new position in shares of Bristol-Myers Squibb in the 4th quarter valued at $1,139,000. 76.41% of the stock is currently owned by institutional investors.

Bristol-Myers Squibb Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Thursday, August 1st. Shareholders of record on Friday, July 5th will be given a dividend of $0.60 per share. This represents a $2.40 annualized dividend and a dividend yield of 5.78%. The ex-dividend date of this dividend is Friday, July 5th. Bristol-Myers Squibb’s payout ratio is -77.42%.

About Bristol-Myers Squibb

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.